EGFR and lung cancer: Superiority of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) to platinum-based chemotherapy in terms of progression-free survival (PFS) in EGFR-mutated lung cancers has been reported in several phase III trials as a first-line treatment (Zhou et al., 2011, Rosell et al., 2012, Mok et al., 2009, Mitsudomi et al., 2010, Maemondo et al., 2010).